EUVIMEDEUVIMED entdecken
Crossref

Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists

Damla Sürmeli iD, Kathleen M Sicinski, Tristan C Dinsmore, Venkata S Raman, Vittorio Montanari iD, Martin Beinborn, Krishna Kumar iD

Journal of Medicinal Chemistry · 11.06.2026 · 69 (11) · 13807-13819

DOI: 10.1021/acs.jmedchem.6c00745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.05.2026. Verfasst von Damla Sürmeli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Tufts University, Medford, Massachusetts 02155, United States. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Peptides. Die Arbeit nennt 48 Literaturangaben. Gefördert von: NIDDK NIH HHS, NIA NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unimolecular multiagonists integrating GLP-1R/GIPR, and increasingly GCGR agonism, have altered the landscape of peptide therapeutics for metabolic syndrome. This progress has shifted the field from optimizing individual ligands to engineering defined receptor selectivity (balance) and, in some cases, pathway-selective signaling (bias) within a single-peptide scaffold. Despite this momentum, tuning ‘balance’ and ‘bias’ remains difficult because small sequence changes can have receptor-dependent, nonintuitive effects, and meaningful retuning often requires wholesale scaffold redesign. Here, we implement a systematic strategy based on simple N-terminal chemical modifications across dual- and triagonist templates to decouple these variables. Because the peptide N-terminus is buried within the membrane-embedded transmembrane core of class B GPCRs, localized chemical edits at this site provide a sensitive lever for reweighting receptor activation. These minimal changes can alter signaling preference without loss of efficacy, expanding the design grammar and offer rapid tuning of potency, efficacy, and bias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsPeptidesHumansLigandsSignal TransductionAnimalsStructure-Activity Relationship

Substanzen

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsLigandsPeptides

Autor:innen und Institutionen

  • Department of Chemistry, Tufts University, Medford, Massachusetts 02155, United States.
  • Molecular Pharmacology Research Center, Tufts Medical Center, Boston, Massachusetts 02111, United States.

ORCID-Profile: Damla Sürmeli, Vittorio Montanari, Krishna Kumar

Förderung

  • NIDDK NIH HHS
  • NIA NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

Sürmeli, D., Sicinski, K. M., Dinsmore, T. C., Raman, V. S., Montanari, V., Beinborn, M., & Kumar, K. (2026). Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists. Journal of Medicinal Chemistry, 69(11), 13807-13819. https://doi.org/10.1021/acs.jmedchem.6c00745

Vancouver

Sürmeli D, Sicinski KM, Dinsmore TC, Raman VS, Montanari V, Beinborn M, et al. Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists. Journal of Medicinal Chemistry. 2026;69(11):13807-13819. doi:10.1021/acs.jmedchem.6c00745

BibTeX
@article{Srmeli2026,
  author = {Sürmeli, Damla and Sicinski, Kathleen M and Dinsmore, Tristan C and Raman, Venkata S and Montanari, Vittorio and Beinborn, Martin and Kumar, Krishna},
  title = {Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {11},
  pages = {13807--13819},
  doi = {10.1021/acs.jmedchem.6c00745}
}
Kostenlos starten →